Supplementary Material 44 Within-trial cost effectiveness scenario analysis – multi-level regression analysis of within-trial costs and QALYs

	Costs (95% CI) [P(most costly)]	QALYs (95% CI) [P(most effective)]	ICER	Incremental net health benefit (95% CI)		
				k=£15,000 [Probability of being cost-effective]	k=£20,000	k=£30,000
Control	£655.92 (479.58, 820.12) [0.043]	17.79448 (17.77295, 17.81666) [0.099]		- - [0.245]	- - [0.204]	- - [0.171]
SWAL only	£733.89 (600.14, 883.22) [0.219]	17.80323 (17.78059, 17.82527) [0.332]	£8,909.12	0.004 (-0.023, 0.032) [0.361]	0.005 (-0.021, 0.031) [0.355]	0.006 (-0.019, 0.031) [0.35]
SWAL plus desk	£803.55 (666.95, 943.34) [0.738]	17.80739 (17.78728, 17.82711) [0.569]	£16,762.95	0.003 (-0.03, 0.038) [0.394]	0.006 (-0.026, 0.038) [0.441]	0.008 (-0.022, 0.039) [0.479]